Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Metabolic vulnerability of cisplatin-resistant cancers.

Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S, Joseph A, Astesana V, Pietrocola F, Wu GS, Castedo M, Kroemer G.

EMBO J. 2018 Jul 13;37(14). pii: e98597. doi: 10.15252/embj.201798597. Epub 2018 Jun 6.

PMID:
29875130
2.

Caspase 2 in mitotic catastrophe: The terminator of aneuploid and tetraploid cells.

Vitale I, Manic G, Castedo M, Kroemer G.

Mol Cell Oncol. 2017 Mar 10;4(3):e1299274. doi: 10.1080/23723556.2017.1299274. eCollection 2017.

3.

Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.

Jemaà M, Manic G, Lledo G, Lissa D, Reynes C, Morin N, Chibon F, Sistigu A, Castedo M, Vitale I, Kroemer G, Abrieu A.

Oncotarget. 2016 Jan 5;7(1):885-901. doi: 10.18632/oncotarget.6432.

4.

Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.

Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G.

Ann Oncol. 2015 Dec;26(12):2470-7. doi: 10.1093/annonc/mdv393. Epub 2015 Sep 19.

PMID:
26387143
5.

PARP and other prospective targets for poisoning cancer cell metabolism.

Michels J, Obrist F, Castedo M, Vitale I, Kroemer G.

Biochem Pharmacol. 2014 Nov 1;92(1):164-71. doi: 10.1016/j.bcp.2014.08.026. Epub 2014 Sep 6. Review.

PMID:
25199458
6.

MCL-1 dependency of cisplatin-resistant cancer cells.

Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G.

Biochem Pharmacol. 2014 Nov 1;92(1):55-61. doi: 10.1016/j.bcp.2014.07.029. Epub 2014 Aug 12.

PMID:
25107702
7.

Systems biology of cisplatin resistance: past, present and future.

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G.

Cell Death Dis. 2014 May 29;5:e1257. doi: 10.1038/cddis.2013.428. Review.

8.

Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention.

Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, Boilève A, Obrist F, Bordenave C, Garcia P, Michels J, Jemaà M, Kepp O, Castedo M, Kroemer G.

Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3020-5. doi: 10.1073/pnas.1318440111. Epub 2014 Feb 10.

9.

Predictive biomarkers for cancer therapy with PARP inhibitors.

Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G.

Oncogene. 2014 Jul 24;33(30):3894-907. doi: 10.1038/onc.2013.352. Epub 2013 Sep 16. Review.

PMID:
24037533
10.

Characterization of novel MPS1 inhibitors with preclinical anticancer activity.

Jemaà M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U, Koppitz M, Lienau P, Prechtl S, Schulze V, Siemeister G, Wengner AM, Mumberg D, Ziegelbauer K, Abrieu A, Castedo M, Vitale I, Kroemer G.

Cell Death Differ. 2013 Nov;20(11):1532-45. doi: 10.1038/cdd.2013.105. Epub 2013 Aug 9.

11.

Immunological control of cell cycle aberrations for the avoidance of oncogenesis: the case of tetraploidy.

Senovilla L, Galluzzi L, Castedo M, Kroemer G.

Ann N Y Acad Sci. 2013 May;1284:57-61. doi: 10.1111/nyas.12072.

PMID:
23651194
12.

Cisplatin resistance associated with PARP hyperactivation.

Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, Sukkurwala AQ, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Dessen P, Saparbaev M, Soria JC, Castedo M, Kroemer G.

Cancer Res. 2013 Apr 1;73(7):2271-80. doi: 10.1158/0008-5472.CAN-12-3000.

13.

Functions of BCL-X L at the Interface between Cell Death and Metabolism.

Michels J, Kepp O, Senovilla L, Lissa D, Castedo M, Kroemer G, Galluzzi L.

Int J Cell Biol. 2013;2013:705294. doi: 10.1155/2013/705294. Epub 2013 Feb 28.

14.

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells.

Senovilla L, Vitale I, Martins I, Kepp O, Galluzzi L, Zitvogel L, Castedo M, Kroemer G.

Oncoimmunology. 2013 Jan 1;2(1):e22409.

15.

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.

Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G.

Cell Cycle. 2013 Mar 15;12(6):877-83. doi: 10.4161/cc.24034. Epub 2013 Feb 21.

16.

Immunosurveillance against tetraploidization-induced colon tumorigenesis.

Boilève A, Senovilla L, Vitale I, Lissa D, Martins I, Métivier D, van den Brink S, Clevers H, Galluzzi L, Castedo M, Kroemer G.

Cell Cycle. 2013 Feb 1;12(3):473-9. doi: 10.4161/cc.23369. Epub 2013 Jan 16.

17.

Cytofluorometric assessment of cell cycle progression.

Vitale I, Jemaà M, Galluzzi L, Metivier D, Castedo M, Kroemer G.

Methods Mol Biol. 2013;965:93-120. doi: 10.1007/978-1-62703-239-1_6.

PMID:
23296653
18.

Vitamin B6 metabolism influences the intracellular accumulation of cisplatin.

Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P, Vacchelli E, Chatelut E, Castedo M, Kroemer G.

Cell Cycle. 2013 Feb 1;12(3):417-21. doi: 10.4161/cc.23275. Epub 2012 Feb 1.

19.

Transgenerational cell fate profiling: a method for the graphical presentation of complex cell cycle alterations.

Jemaà M, Galluzzi L, Kepp O, Castedo M, Rello-Varona S, Vitale I, Kroemer G.

Cell Cycle. 2013 Jan 1;12(1):183-90. doi: 10.4161/cc.23046. Epub 2012 Dec 19.

20.

Immunosurveillance against cancer-associated hyperploidy.

Senovilla L, Galluzzi L, Marino G, Vitale I, Castedo M, Kroemer G.

Oncotarget. 2012 Nov;3(11):1270-1. No abstract available.

21.

An immunosurveillance mechanism controls cancer cell ploidy.

Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, Shen S, Mariño G, Criollo A, Boilève A, Job B, Ladoire S, Ghiringhelli F, Sistigu A, Yamazaki T, Rello-Varona S, Locher C, Poirier-Colame V, Talbot M, Valent A, Berardinelli F, Antoccia A, Ciccosanti F, Fimia GM, Piacentini M, Fueyo A, Messina NL, Li M, Chan CJ, Sigl V, Pourcher G, Ruckenstuhl C, Carmona-Gutierrez D, Lazar V, Penninger JM, Madeo F, López-Otín C, Smyth MJ, Zitvogel L, Castedo M, Kroemer G.

Science. 2012 Sep 28;337(6102):1678-84.

PMID:
23019653
22.

Tetraploid cancer cell precursors in ovarian carcinoma.

Castedo M, Senovilla L, Vitale I, Kroemer G.

Cell Cycle. 2012 Sep 1;11(17):3157-8. doi: 10.4161/cc.21722. Epub 2012 Aug 16. No abstract available.

23.

Prognostic impact of vitamin B6 metabolism in lung cancer.

Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, Shen S, Tailler M, Niso-Santano M, Morselli E, Criollo A, Adjemian S, Jemaà M, Chaba K, Pailleret C, Michaud M, Pietrocola F, Tajeddine N, de La Motte Rouge T, Araujo N, Morozova N, Robert T, Ripoche H, Commo F, Besse B, Validire P, Fouret P, Robin A, Dorvault N, Girard P, Gouy S, Pautier P, Jägemann N, Nickel AC, Marsili S, Paccard C, Servant N, Hupé P, Behrens C, Behnam-Motlagh P, Kohno K, Cremer I, Damotte D, Alifano M, Midttun O, Ueland PM, Lazar V, Dessen P, Zischka H, Chatelut E, Castedo M, Madeo F, Barillot E, Thomale J, Wistuba II, Sautès-Fridman C, Zitvogel L, Soria JC, Harel-Bellan A, Kroemer G.

Cell Rep. 2012 Aug 30;2(2):257-69. doi: 10.1016/j.celrep.2012.06.017. Epub 2012 Jul 26.

24.

Preferential killing of p53-deficient cancer cells by reversine.

Jemaà M, Galluzzi L, Kepp O, Boilève A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antoccia A, Castedo M, Vitale I, Kroemer G.

Cell Cycle. 2012 Jun 1;11(11):2149-58. doi: 10.4161/cc.20621. Epub 2012 Jun 1.

PMID:
22592527
25.

Selective killing of p53-deficient cancer cells by SP600125.

Jemaà M, Vitale I, Kepp O, Berardinelli F, Galluzzi L, Senovilla L, Mariño G, Malik SA, Rello-Varona S, Lissa D, Antoccia A, Tailler M, Schlemmer F, Harper F, Pierron G, Castedo M, Kroemer G.

EMBO Mol Med. 2012 Jun;4(6):500-14. doi: 10.1002/emmm.201200228. Epub 2012 Mar 21.

26.

Autophagic removal of micronuclei.

Rello-Varona S, Lissa D, Shen S, Niso-Santano M, Senovilla L, Mariño G, Vitale I, Jemaá M, Harper F, Pierron G, Castedo M, Kroemer G.

Cell Cycle. 2012 Jan 1;11(1):170-6. doi: 10.4161/cc.11.1.18564. Epub 2012 Jan 1.

PMID:
22185757
27.

Molecular mechanisms of cisplatin resistance.

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G.

Oncogene. 2012 Apr 12;31(15):1869-83. doi: 10.1038/onc.2011.384. Epub 2011 Sep 5. Review.

PMID:
21892204
28.

Cytofluorometric purification of diploid and tetraploid cancer cells.

Castedo M, Galluzzi L, Vitale I, Senovilla L, Métivier D, Jèmaà M, Rello-Varona S, Kroemer G.

Methods Mol Biol. 2011;761:47-63. doi: 10.1007/978-1-61779-182-6_3.

PMID:
21755440
29.

Mitotic catastrophe: a mechanism for avoiding genomic instability.

Vitale I, Galluzzi L, Castedo M, Kroemer G.

Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92. doi: 10.1038/nrm3115. Epub 2011 Apr 29. Review.

PMID:
21527953
30.

An automated fluorescence videomicroscopy assay for the detection of mitotic catastrophe.

Rello-Varona S, Kepp O, Vitale I, Michaud M, Senovilla L, Jemaà M, Joza N, Galluzzi L, Castedo M, Kroemer G.

Cell Death Dis. 2010;1:e25. doi: 10.1038/cddis.2010.6.

31.

Illicit survival of cancer cells during polyploidization and depolyploidization.

Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaà M, Castedo M, Kroemer G.

Cell Death Differ. 2011 Sep;18(9):1403-13. doi: 10.1038/cdd.2010.145. Epub 2010 Nov 12. Review.

32.

A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis.

Castedo M, Vitale I, Kroemer G.

Oncogene. 2010 Nov 4;29(44):5869-72. doi: 10.1038/onc.2010.392. Epub 2010 Aug 30. Review.

PMID:
20802535
33.

Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells.

Vitale I, Jemaà M, Senovilla L, Galluzzi L, Rello-Varona S, Metivier D, Ripoche H, Lazar V, Dessen P, Castedo M, Kroemer G.

Cell Cycle. 2010 Jul 15;9(14):2823-9. Epub 2010 Jul 3.

PMID:
20686359
34.

Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos.

Vitale I, Senovilla L, Jemaà M, Michaud M, Galluzzi L, Kepp O, Nanty L, Criollo A, Rello-Varona S, Manic G, Métivier D, Vivet S, Tajeddine N, Joza N, Valent A, Castedo M, Kroemer G.

EMBO J. 2010 Apr 7;29(7):1272-84. doi: 10.1038/emboj.2010.11. Epub 2010 Feb 25.

35.

Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells.

Shen S, Kepp O, Martins I, Vitale I, Souquère S, Castedo M, Pierron G, Kroemer G.

Cell Cycle. 2010 Jan 15;9(2):377-83. Epub 2010 Jan 29.

PMID:
20023420
36.

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.

Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, Kroemer G, Deutsch E.

Cell Cycle. 2009 Oct 1;8(19):3172-81. Epub 2009 Oct 4.

PMID:
19755861
37.

Mitochondrial gateways to cancer.

Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, Michaud M, Zischka H, Castedo M, Kroemer G.

Mol Aspects Med. 2010 Feb;31(1):1-20. doi: 10.1016/j.mam.2009.08.002. Epub 2009 Aug 19. Review.

PMID:
19698742
38.

Factors associated to patients' noncompliance with hypertension treatment.

Dosse C, Cesarino CB, Martin JF, Castedo MC.

Rev Lat Am Enfermagem. 2009 Mar-Apr;17(2):201-6.

39.

Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes.

Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Castedo M, Cidlowski JA, Ciechanover A, Cohen GM, De Laurenzi V, De Maria R, Deshmukh M, Dynlacht BD, El-Deiry WS, Flavell RA, Fulda S, Garrido C, Golstein P, Gougeon ML, Green DR, Gronemeyer H, Hajnóczky G, Hardwick JM, Hengartner MO, Ichijo H, Jäättelä M, Kepp O, Kimchi A, Klionsky DJ, Knight RA, Kornbluth S, Kumar S, Levine B, Lipton SA, Lugli E, Madeo F, Malomi W, Marine JC, Martin SJ, Medema JP, Mehlen P, Melino G, Moll UM, Morselli E, Nagata S, Nicholson DW, Nicotera P, Nuñez G, Oren M, Penninger J, Pervaiz S, Peter ME, Piacentini M, Prehn JH, Puthalakath H, Rabinovich GA, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Scorrano L, Simon HU, Steller H, Tschopp J, Tsujimoto Y, Vandenabeele P, Vitale I, Vousden KH, Youle RJ, Yuan J, Zhivotovsky B, Kroemer G.

Cell Death Differ. 2009 Aug;16(8):1093-107. doi: 10.1038/cdd.2009.44. Epub 2009 Apr 17. Review.

40.

p53 represses the polyploidization of primary mammary epithelial cells by activating apoptosis.

Senovilla L, Vitale I, Galluzzi L, Vivet S, Joza N, Younes AB, Rello-Varona S, Castedo M, Kroemer G.

Cell Cycle. 2009 May 1;8(9):1380-5. Epub 2009 May 26.

PMID:
19342895
41.

The inositol 1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1.

Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, Joza N, Vitale I, Morselli E, Tailler M, Castedo M, Maiuri MC, Molgó J, Szabadkai G, Lavandero S, Kroemer G.

Cell Death Differ. 2009 Jul;16(7):1006-17. doi: 10.1038/cdd.2009.34. Epub 2009 Mar 27.

42.

Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.

Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierré A, Golsteyn RM, Bourhis J, Kroemer G, Deutsch E.

Cell Cycle. 2009 Apr 15;8(8):1196-205. Epub 2009 Apr 16.

PMID:
19305158
43.

Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5.

Rello-Varona S, Vitale I, Kepp O, Senovilla L, Jemaá M, Métivier D, Castedo M, Kroemer G.

Cell Cycle. 2009 Apr 1;8(7):1030-5. Epub 2009 Apr 27.

PMID:
19270519
44.

Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells.

Vitale I, Senovilla L, Galluzzi L, Criollo A, Vivet S, Castedo M, Kroemer G.

Cell Cycle. 2008 Jul 1;7(13):1956-61.

PMID:
18642443
45.

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.

Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G.

Cancer Res. 2008 Jul 1;68(13):5301-8. doi: 10.1158/0008-5472.CAN-08-0237.

46.

Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway.

Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L, Olaussen KA, Lazar V, Prudhomme M, Golsteyn RM, Castedo M, Kroemer G.

PLoS One. 2007 Dec 26;2(12):e1337.

47.

Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.

Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E.

Oncogene. 2008 May 22;27(23):3244-55. Epub 2007 Dec 17.

PMID:
18084327
48.

Apaf-1 Deficiency Causes Chromosomal Instability.

Mouhamad S, Galluzzi L, Zermati Y, Castedo M, Kroemer G.

Cell Cycle. 2007 Dec;6(24):3103-3107. Epub 2007 Sep 14.

PMID:
18073531
49.

Nonapoptotic role for Apaf-1 in the DNA damage checkpoint.

Zermati Y, Mouhamad S, Stergiou L, Besse B, Galluzzi L, Boehrer S, Pauleau AL, Rosselli F, D'Amelio M, Amendola R, Castedo M, Hengartner M, Soria JC, Cecconi F, Kroemer G.

Mol Cell. 2007 Nov 30;28(4):624-37. Erratum in: Mol Cell. 2012 Oct 26;48(2):322-4.

50.

Depletion of endonuclease G selectively kills polyploid cells.

Büttner S, Carmona-Gutierrez D, Vitale I, Castedo M, Ruli D, Eisenberg T, Kroemer G, Madeo F.

Cell Cycle. 2007 May 2;6(9):1072-6. Epub 2007 May 27.

PMID:
17471024

Supplemental Content

Loading ...
Support Center